COVID second booster adverse reactions fewer than after first one - CDC
andresr/E+ via Getty Images


Individuals 50 years of age and older who received a second COVID-19 mRNA booster have reported fewer injection site and systemic reactions compared to after receiving the first booster.
A recent study published in the CDC's MMWR based on 16.8M people in the age group that got the second booster found that out of 8,515 events reported, 95% were considered non-serious. This was based on reports made the the Vaccine Adverse Events Reporting System.

For Moderna (NASDAQ:MRNA) vaccine recipients, ~70% reported an injection site reaction and ~60% a systemic reaction after the first booster. After the second one, the figures dropped to, respectively, ~60% and ~50%.
For the Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) vaccine, after the first booster, the figures were ~58% and ~53%. After the second booster, the figures dropped to ~49% and ~45%.
U.S. health authorities are now focused more on rolling out a booster campaign in September with shots that target Omicron and its subvariants.